- Home
- BYSI vs EPIX Comparison
BYSI vs EPIX Comparison
Compare BYSI & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYSI
- EPIX
- Stock Information
- Founded
- BYSI 2010
- EPIX 2009
- Country
- BYSI United States
- EPIX Canada
- Employees
- BYSI N/A
- EPIX N/A
- Industry
- BYSI Biotechnology: Pharmaceutical Preparations
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- BYSI Health Care
- EPIX Health Care
- Exchange
- BYSI Nasdaq
- EPIX Nasdaq
- Market Cap
- BYSI 71.0M
- EPIX 75.9M
- IPO Year
- BYSI 2017
- EPIX N/A
- Fundamental
- Price
- BYSI $2.18
- EPIX $1.87
- Analyst Decision
- BYSI
- EPIX Hold
- Analyst Count
- BYSI 0
- EPIX 3
- Target Price
- BYSI N/A
- EPIX $2.00
- AVG Volume (30 Days)
- BYSI 92.5K
- EPIX 401.6K
- Earning Date
- BYSI 08-11-2025
- EPIX 08-04-2025
- Dividend Yield
- BYSI N/A
- EPIX N/A
- EPS Growth
- BYSI N/A
- EPIX N/A
- EPS
- BYSI N/A
- EPIX N/A
- Revenue
- BYSI N/A
- EPIX N/A
- Revenue This Year
- BYSI N/A
- EPIX N/A
- Revenue Next Year
- BYSI N/A
- EPIX N/A
- P/E Ratio
- BYSI N/A
- EPIX N/A
- Revenue Growth
- BYSI N/A
- EPIX N/A
- 52 Week Low
- BYSI $0.98
- EPIX $1.40
- 52 Week High
- BYSI $3.44
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- BYSI 44.93
- EPIX 65.00
- Support Level
- BYSI $2.15
- EPIX $1.68
- Resistance Level
- BYSI $2.35
- EPIX $1.88
- Average True Range (ATR)
- BYSI 0.13
- EPIX 0.04
- MACD
- BYSI -0.05
- EPIX 0.02
- Stochastic Oscillator
- BYSI 8.57
- EPIX 90.48
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.